系统性红斑狼疮患者接种新型冠状病毒疫苗的建议及依据

Recommendations and Evidence for COVID-19 Vaccine in Patients with Systemic Lupus Erythematosus

在新型冠状病毒肺炎(COVID-19)疫情持续的当下,自身免疫性疾病导致的免疫异常和应用免疫抑制剂治疗导致的免疫功能低下,使得系统性红斑狼疮(SLE)患者对新型冠状病毒(SARS-CoV-2)的易感性更高。同时,感染是SLE患者死亡的重要危险因素,也可导致SLE患者病情活跃、恶化进而使预后更差。但是,目前SLE患者接种新型冠状病毒疫苗的临床数据尚不充分,使得该类患者的新型冠状病毒疫苗接种存在一定争议。本文从我国目前广泛接种的3类疫苗和SLE的基本情况出发,结合COVID-19与SLE患者相关病例及SLE患者接种新型冠状病毒疫苗的基本情况,通过梳理国际上新型冠状病毒疫苗接种建议,提出SLE患者的新型冠状病毒疫苗接种建议,仅供医学专业医务工作者参考。

In the ongoing COVID-19 pandemic,systemic lupus erythematosus,due to immune abnormalities caused by autoimmune diseases and low immune function due to immunosuppressant therapy,patients with systemic lupus erythematosus(SLE)have a higher susceptibility to SARS-COV-2.Meanwhile,infection is an important risk factor for death in patients with SLE,and can also lead to active and worsening of patients with SLE,and resulting in a worse prognosis.However,there are insufficient clinical data on COVID-19 vaccine in patients with SLE,so that COVID-19 vaccine in patients have certain controversies.Based on three types of vaccines widely inoculated in China and the basic situation of SLE,this paper proposes recommendations of COVID-19 vaccine for SLE patients by combing the international recommendations on COVID-19 vaccine for reference of medical professionals.